Table 4 Tumor response per RECIST v1.1
25 mg (n = 1) | 50 mg (n = 3) | 75 mg (n = 3) | 100 mg (n = 10) | 125 mg (n = 10) | 150 mg (n = 10) | 175 mg (n = 3) | All patients (n = 40) | |
|---|---|---|---|---|---|---|---|---|
Best overall response, n (%) | ||||||||
Complete response | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Partial response | 0 | 0 | 0 | 0 | 1 (10.0) | 1 (10.0) | 0 | 2 (5.0) |
Stable disease | 0 | 2 (66.7) | 1 (33.3) | 7 (70.0) | 4 (40.0) | 7 (70.0) | 2 (66.7) | 23 (57.5) |
Progressive disease | 1 | 1 (33.3) | 2 (66.7) | 3 (30.0) | 5 (50.0) | 2 (20.0) | 1 (33.3) | 15 (37.5) |
DCR, % (95% CI) | 0 (NR) | 66.7 (9.4–99.2) | 33.3 (0.8–90.6) | 70.0 (34.8–93.3) | 50.0 (18.7–81.3) | 80.0 (44.4–97.5) | 66.7 (9.4–99.2) | 62.5 (45.8–77.3) |